Chromogranin A

Cancer

Report in 120Hrs

At Home

No Fasting Required

Details

Neuroendocrine tumor marker.

₹7,769₹11,098

30% OFF

Chromogranin A Test Information Guide

Why is it done?
- Test Measurement: Chromogranin A is a protein released by neuroendocrine cells. This blood test measures its levels to detect neuroendocrine tumors and monitor disease progression.
- Primary Indications: Diagnosis and monitoring of neuroendocrine tumors (NETs), including carcinoid tumors and pheochromocytomas; evaluation of symptoms suggestive of neuroendocrine malignancy; tumor surveillance during and after treatment.
- Typical Timing: Performed during initial diagnosis workup, baseline measurement before treatment, periodic monitoring every 3-6 months during therapy, and long-term surveillance for recurrence in patients with history of neuroendocrine tumors.
- Clinical Scenarios: Patients with flushing, diarrhea, or abdominal pain; family history of multiple endocrine neoplasia (MEN); prior diagnosis of neuroendocrine tumor; assessment of treatment response.
Normal Range
- Reference Range: 0-100 ng/mL (nanograms per milliliter) or 0-225 pmol/L (picomoles per liter) depending on laboratory methodology. Different labs may have slightly different reference ranges.
- Normal Result: Chromogranin A levels below the upper limit of normal suggest absence of neuroendocrine tumor or low tumor burden. Generally indicates healthy neuroendocrine function.
- Abnormal Result: Elevated levels (>100 ng/mL) suggest possible neuroendocrine tumor or other conditions affecting neuroendocrine cells. Higher elevations generally correlate with larger tumor burden.
- Borderline Values: Results in the upper normal to mildly elevated range (100-200 ng/mL) may warrant repeat testing and additional imaging to rule out neuroendocrine pathology.
- Units of Measurement: Expressed in ng/mL, pmol/L, or μg/L depending on laboratory standards and regional conventions.
Interpretation
- Mildly Elevated (100-500 ng/mL): May indicate small neuroendocrine tumors, early disease, or benign neuroendocrine proliferation. Requires imaging studies and clinical correlation.
- Moderately Elevated (500-1000 ng/mL): Suggestive of significant neuroendocrine tumor burden. Warrants comprehensive imaging and specialist evaluation.
- Markedly Elevated (>1000 ng/mL): Highly suggestive of advanced neuroendocrine malignancy or extensive metastatic disease. Indicates need for urgent evaluation and treatment planning.
- Decreasing Trend: In patients undergoing treatment, declining levels indicate positive treatment response. Progressive decline may suggest tumor regression.
- Increasing Trend: Rising levels during treatment suggest disease progression or treatment failure. May indicate need for therapy modification.
- Factors Affecting Results: Proton pump inhibitors (elevate levels), some antipsychotics, atropine, renal insufficiency, stress, recent meals (avoid with certain preparations), specimen handling, and concurrent medications can affect chromogranin A levels.
- Clinical Significance: Chromogranin A serves as a tumor marker with high sensitivity for neuroendocrine tumors but moderate specificity. Must be interpreted alongside clinical presentation, imaging findings, and other neuroendocrine markers.
Associated Organs
- Primary Organ System: Neuroendocrine system including pancreas, gastrointestinal tract, lungs, adrenal medulla, and thyroid C-cells. Chromogranin A is produced by neuroendocrine cells throughout the body.
- Common Tumor Origins: Pancreatic neuroendocrine tumors (PNETs), carcinoid tumors of the small intestine and lungs, pheochromocytomas, medullary thyroid carcinomas, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Associated Conditions: Multiple endocrine neoplasia type 1 (MEN1), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (NF1), familial pheochromocytoma/paraganglioma syndromes, carcinoid syndrome, and metastatic neuroendocrine disease.
- Related Benign Conditions: Chronic kidney disease, atrophic gastritis, inflammatory bowel disease, and parkinson's disease can cause mild elevation of chromogranin A.
- Potential Complications: Undiagnosed neuroendocrine tumors may lead to carcinoid crisis, hypertensive emergency (pheochromocytoma), severe diarrhea and flushing, and metastatic disease complications if left untreated.
- Disease Monitoring: Chromogranin A helps track disease progression, assess treatment efficacy, and detect recurrence in patients with established neuroendocrine malignancy.
Follow-up Tests
- Confirmatory Testing: 24-hour urine metanephrines and catecholamines (for pheochromocytoma), 5-HIAA (5-hydroxyindoleacetic acid) urine test, plasma and urine metanephrines, fasting gastrin level.
- Imaging Studies: CT or MRI of chest/abdomen/pelvis, somatostatin receptor scintigraphy (SRS or OctreoScan), PET-CT scanning, endoscopic ultrasound (EUS), and 68Ga-DOTATATE PET/CT for neuroendocrine tumor localization.
- Additional Biomarkers: Chromogranin B, neuron-specific enolase (NSE), pancreatic polypeptide, vasoactive intestinal peptide (VIP), insulin level, proinsulin, substance P, and other hormone-specific markers depending on suspected tumor type.
- Pathology and Genetics: Tumor biopsy with immunohistochemistry, Ki-67 proliferation index, genetic testing for MEN1, RET, VHL, NF1, and SDH mutations in familial cases.
- Monitoring Frequency: Every 3 months during active treatment, every 6 months during surveillance for stable disease, every 3-6 months for recurrence monitoring, and annually for long-term follow-up after successful treatment.
- Complementary Tests: Complete metabolic panel, liver function tests, complete blood count, coagulation studies, and thyroid function tests to assess organ involvement and treatment toxicity.
- Specialist Consultation: Referral to endocrinology, oncology, gastroenterology, or neuroendocrine tumor specialists for comprehensive evaluation and management planning.
Fasting Required?
- Fasting Requirement: Yes, fasting is recommended for optimal results.
- Fasting Duration: Fast for 8-12 hours prior to blood draw. Typically performed in the morning after an overnight fast.
- Dietary Instructions: No food or beverages except water allowed after midnight on the day of testing. Avoid alcohol for 24 hours before the test.
- Medications to Avoid: Stop proton pump inhibitors (omeprazole, lansoprazole) 3-5 days before testing if possible, as they significantly elevate chromogranin A. Discontinue H2-receptor antagonists 48 hours prior. Consult physician before stopping other medications.
- Additional Preparation: Avoid strenuous exercise 24 hours before testing. Remain calm and seated for 5-10 minutes before blood draw to reduce stress-related elevation of chromogranin A.
- Sample Collection: Blood sample collected in appropriate tube (typically EDTA or serum separator tube), handled carefully, and transported promptly to laboratory. Improper handling may result in false elevation.
- Special Circumstances: Patients with acute illness, stress, or severe anxiety may have falsely elevated results. Repeat testing may be warranted for confirmation. Patients on hemodialysis should inform the lab due to renal retention of chromogranin A.

How our test process works!